MAP2K1 V211D

CI-VAR-00004498Explore in graph →CIViC 2805

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
MAP2K1 V211D	Binimetinib + PanitumumabCombination	Predictive	C	Supports Resistance	3	submitted	EID7580 Patients with metastatic colorectal cancer harboring BRAF V601E mutation were treated with binimetinib and panitumumab combination. Gene profiling at progressed tumor revealed MEK1 V211D mutation. V21… (full text at CIViC) PMID 31227518 · Gao et al., 2019 · Open in CIViC	civic
MAP2K1 V211D	MAP855	Predictive	D	Supports Sensitivity Response	3	submitted	EID7581 Patients with metastatic colorectal cancer harboring BRAF V601E mutation were treated with binimetinib and panitumumab combination. Gene profiling at progressed tumor revealed MEK1 V211D mutation. V21… (full text at CIViC) PMID 31227518 · Gao et al., 2019 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.